2-bromo-1-(6-trifluoromethyl-pyridin-3-yl)-propan-1-one | 481066-16-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-1-(6-trifluoromethyl-pyridin-3-yl)-propan-1-one
• 英文别名: 2-bromo-1-[6-(trifluoromethyl)-3-pyridyl]propan-1-one；1-Propanone, 2-bromo-1-[6-(trifluoromethyl)-3-pyridinyl]-；2-bromo-1-[6-(trifluoromethyl)pyridin-3-yl]propan-1-one
• CAS: 481066-16-4
• 化学式: C₉H₇BrF₃NO
• 分子量: 282.06
• InChiKey: OXNTWJOZKBLNBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-bromo-1-(6-trifluoromethyl-pyridin-3-yl)-propan-1-one 在 一水合肼 、 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 、 正丁醇 为溶剂， 反应 22.5h， 生成 4-(2,6-difluoro-4-methoxy-phenyl)-3-methoxy-6-methyl-5-(trifluoromethyl-pyridin-3-yl)-pyridazine
  参考文献：
  名称：

  [EN] NOVEL 5-(PYRIDIN-3-YL)-PYRIDANIZE DERIVATIVES AND THEIR USE AS MICROBICIDES
  [FR] NOUVEAUX DÉRIVÉS DE 5-(PYRIDIN-3-YL)-PYRIDAZINE ET LEUR UTILISATION EN TANT QUE MICROBICIDES

  摘要：

  本发明涉及一种新的吡啶嗪衍生物，其化学式为（I），作为活性成分具有微生物杀菌活性，特别是具有杀真菌活性。

  公开号：

  WO2011076501A1
• 作为产物：
  描述：

  6-三氟甲基烟酸乙酯 在 正丁基锂 、 氢溴酸 、 溴 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 、 溶剂黄146 为溶剂， 反应 0.5h， 生成 2-bromo-1-(6-trifluoromethyl-pyridin-3-yl)-propan-1-one
  参考文献：
  名称：

  [EN] NOVEL 5-(PYRIDIN-3-YL)-PYRIDANIZE DERIVATIVES AND THEIR USE AS MICROBICIDES
  [FR] NOUVEAUX DÉRIVÉS DE 5-(PYRIDIN-3-YL)-PYRIDAZINE ET LEUR UTILISATION EN TANT QUE MICROBICIDES

  摘要：

  本发明涉及一种新的吡啶嗪衍生物，其化学式为（I），作为活性成分具有微生物杀菌活性，特别是具有杀真菌活性。

  公开号：

  WO2011076501A1

文献信息

• Halogenated sulfonamide derivatives
  申请人：Jubian Vrej

  公开号：US20070213376A1

  公开（公告）日：2007-09-13

  This invention is directed to halogenated sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention. Furthermore, the present invention is directed to use of a compound of the invention for the manufacture of a medicament for treating a subject suffering from depression, anxiety or obesity.

  该发明涉及卤代磺胺衍生物，这些衍生物是NPY Y5受体的配体。该发明提供了一种包含该发明化合物的治疗有效量和药学上可接受的载体的药物组合物。该发明还提供了一种通过混合该发明化合物的治疗有效量和药学上可接受的载体制备的药物组合物。此外，该发明还提供了一种制备药物组合物的方法，包括混合该发明化合物的治疗有效量和药学上可接受的载体。该发明还提供了一种治疗患有抑郁症的受试者的方法，包括向受试者投与该发明化合物的量。该发明还提供了一种治疗患有焦虑症的受试者的方法，包括向受试者投与该发明化合物的量。该发明还提供了一种治疗患有肥胖症的受试者的方法，包括向受试者投与该发明化合物的量。此外，本发明还涉及使用该发明化合物制造用于治疗患有抑郁症、焦虑症或肥胖症的受试者的药物的用途。
• [EN] HALOGENATED SULFONAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE SULFONAMIDE HALOGÉNÉS
  申请人：LUNDBECK & CO AS H

  公开号：WO2007103295A2

  公开（公告）日：2007-09-13

  [EN] This invention is directed to halogenated sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention. Furthermore, the present invention is directed to use of a compound of the invention for the manufacture of a medicament for treating a subject suffering from depression, anxiety or obesity.
  [FR] Cette invention concerne des dérivés de sulfonamide halogénés, lesquels sont des ligands du récepteur Y5 du neuropeptide Y (NPY). L'invention concerne une composition pharmaceutique comprenant une quantité efficace du point de vue thérapeutique d'un composé de l'invention et un véhicule acceptable du point de vue pharmaceutique. Cette invention concerne également une composition pharmaceutique formée en mélangeant une quantité efficace du point de vue thérapeutique d'un composé de l'invention et un véhicule acceptable du point de vue pharmaceutique. Cette invention concerne en plus un procédé servant à fabriquer une composition pharmaceutique consistant à combiner une quantité efficace du point de vue thérapeutique d'un composé de l'invention et un véhicule acceptable du point de vue pharmaceutique. Cette invention concerne également un procédé de traitement d'un sujet souffrant de dépression, lequel consiste à administrer au sujet une certaine quantité d'un composé de la présente invention. Cette invention concerne également un procédé de traitement d'un sujet souffrant d'anxiété, lequel consiste à administrer au sujet une certaine quantité d'un composé de la présente invention. Cette invention concerne également un procédé de traitement d'un sujet souffrant d'obésité, lequel consiste à administrer au sujet une certaine quantité d'un composé de la présente invention. En outre, la présente invention concerne l'utilisation d'un composé de l'invention pour la fabrication d'un médicament servant à traiter un sujet souffrant de dépression, d'anxiété ou d'obésité.
• [EN] NOVEL USES OF HALOGENATED ALKYL SULFONAMIDES<br/>[FR] UTILISATIONS INNOVANTES D'ALKYL SULFAMIDES HALOGÉNÉS
  申请人：LUNDBECK & CO AS H

  公开号：WO2009035855A2

  公开（公告）日：2009-03-19

  The present invention relates to methods of treating disorders relating to mood, anxiety, stress, sleep, cognitive impairment/dysfunction, substance dependency/abuse, metabolism, eating and chronic pain comprising administering a therapeutically effective amount of a compound of Formula I, and to uses of a compound of Formula 1 in the manufacture of a medicament for treating said disorders.
• [EN] NOVEL 5-(PYRIDIN-3-YL)-PYRIDANIZE DERIVATIVES AND THEIR USE AS MICROBICIDES<br/>[FR] NOUVEAUX DÉRIVÉS DE 5-(PYRIDIN-3-YL)-PYRIDAZINE ET LEUR UTILISATION EN TANT QUE MICROBICIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2011076501A1

  公开（公告）日：2011-06-30

  The present invention relates to novel pyridazine derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity.

  本发明涉及一种新的吡啶嗪衍生物，其化学式为（I），作为活性成分具有微生物杀菌活性，特别是具有杀真菌活性。